Drug-Coated Balloon Market Size, Share & Analysis | Global | 2025-2032 | Includes: SFA and AV Access
Description
Global Drug-Coated Balloon Market Report
By iData Research - 55 pages - 5 charts, 23 figures
Executive Summary
The global drug-coated balloon market was valued at $523 million in 2025. This market is expected to grow at a CAGR of 5% over the forecast period to reach approximately $735 million by 2032.
The full report suite on the global market for drug-coated balloons covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides detailed market valuation, unit analysis and average selling price data, along with forecasts through 2032 and historical data to 2022. The structure of this report follows the same best-practice format shown in the attached example document, ensuring consistent segmentation, competitive benchmarking and forecasting methodology .
This report provides a focused analysis of the global drug-coated balloon market, including unit sales, procedure numbers, average selling prices, market size, growth trends, market shares and forecasts. It also includes qualitative analysis of market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and competitive positioning across key players.
A key trend shaping this market is the continued refinement of coating technologies and the expansion of clinical applications. Manufacturers are improving drug delivery efficiency, coating durability and biocompatibility, which supports better clinical outcomes. At the same time, the use of drug-coated balloons is expanding beyond traditional peripheral applications into areas such as small vessels, bifurcation lesions and in-stent restenosis. These factors are supporting steady growth and reinforcing the role of drug-coated balloons as a versatile tool across multiple interventional settings.
Despite this positive outlook, the market continues to be influenced by lingering concerns around paclitaxel-based technologies. These concerns have shaped physician behavior and slowed adoption in certain regions. As a result, while the drug-coated balloon market is growing faster than many other balloon categories, its expansion remains tied to clinical confidence, continued research and the development of next-generation drug platforms.
Market Overview
The global drug-coated balloon market includes catheter-based angioplasty balloons that are coated with antiproliferative drugs designed to reduce restenosis following vessel dilation. Unlike traditional balloon angioplasty, which relies only on mechanical expansion, drug-coated balloons deliver medication directly to the vessel wall during inflation, helping prevent re-narrowing of the treated segment.
These devices are used primarily in peripheral vascular interventions, including superficial femoral artery procedures and arteriovenous access interventions. They are also gaining traction in more specialized applications, such as small vessel disease and in-stent restenosis. Their ability to treat lesions without leaving a permanent implant has made them an attractive option in cases where long-term vessel flexibility and future treatment options are important.
The drug-coated balloon market sits between standard PTA balloons and stent-based therapies. Compared with standard balloons, drug-coated balloons offer improved long-term outcomes in selected cases. Compared with stents, they provide a non-implant alternative that can reduce the risk of complications associated with permanent devices. This positioning gives them a distinct role in modern endovascular treatment strategies.
Overall, the drug-coated balloon market is characterized by steady growth, ongoing innovation and a strong link between clinical evidence and commercial performance.
Market Drivers
Drug-Coated Balloon Clinical Performance
One of the main drivers of the drug-coated balloon market is the strong clinical performance demonstrated in many studies. Clinical trials have shown that drug-coated balloons can improve long-term outcomes compared with standard balloons, particularly in reducing restenosis. This makes them an attractive option for physicians treating lesions where durability is a concern.
Because these devices do not leave a permanent implant, they also align with treatment strategies that aim to preserve vessel anatomy and maintain future treatment flexibility. This is especially important in peripheral vascular disease, where patients may require multiple interventions over time.
Increasing Adoption in Complex Lesions
The expansion of drug-coated balloon use into more complex lesion types is another key driver. These devices are being used more frequently in small vessels, bifurcation lesions and in-stent restenosis cases. As physicians gain more experience and confidence in these applications, the total addressable market continues to expand.
Below-the-knee procedures are also an important area of growth. These interventions often involve smaller vessels, where drug-coated balloons can provide an effective treatment option without the need for stent placement. As the number of these procedures increases, demand for drug-coated balloons is expected to grow alongside them.
Pricing Dynamics and Relative Value
While drug-coated balloons are more expensive than standard PTA balloons, their price point is often lower than that of stent-based therapies when considering total procedural cost. As pricing becomes more competitive and as reimbursement structures evolve, drug-coated balloons are becoming a more accessible option in many healthcare systems.
As average selling prices decline over time, adoption is expected to increase, particularly in regions where cost sensitivity has previously limited uptake. This creates a pathway for broader use and supports long-term market growth.
Expansion of Coating Technologies
Advancements in coating technology are also driving market expansion. Manufacturers are working to improve drug transfer efficiency, coating stability and overall device performance. These improvements can lead to better clinical outcomes and increased physician confidence.
In addition, research into alternative drug formulations and delivery methods may help address concerns associated with existing drug platforms. Continued innovation in this area is expected to play a key role in shaping the future of the market.
Market Limiters
Concerns Over Paclitaxel Use
One of the most significant limiters in the drug-coated balloon market is the concern over paclitaxel use. In early 2019, the market experienced a major disruption following studies that suggested a potential link between paclitaxel-coated devices and increased long-term mortality. This led to a sharp decline in physician confidence and a reduction in device usage.
Although further research has provided additional context and the market has begun to recover, the impact of these concerns is still present. Physicians remain cautious, and adoption rates have not fully returned to pre-2019 expectations. This continues to influence both unit growth and overall market value.
Dependence on Clinical Evidence
The drug-coated balloon market is highly dependent on clinical data. While strong evidence can support rapid adoption, negative or uncertain findings can have an equally strong impact in the opposite direction. This creates a level of volatility that is not present in more mature and commoditized device categories.
Manufacturers must continue to invest in clinical studies, post-market surveillance and physician education to maintain confidence and support adoption. These requirements add cost and complexity to product development and commercialization.
Slower Recovery in Certain Segments
Some segments of the drug-coated balloon market have been slower to recover following the paclitaxel-related disruption. This is particularly true in areas where alternative treatment options are readily available or where physician preference has shifted toward other technologies.
As a result, growth in these segments is expected to be gradual rather than rapid. The overall market will continue to expand, but at a pace that reflects both renewed adoption and ongoing caution.
Competitive Pressure from Alternative Therapies
Drug-coated balloons also face competition from other treatment modalities, including standard PTA balloons, stents and atherectomy devices. In some cases, physicians may choose these alternatives based on lesion characteristics, cost considerations or clinical preference.
This competitive environment means that drug-coated balloons must continue to demonstrate clear clinical value in order to maintain and grow their share within the broader peripheral vascular device market.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, competitive analysis, company profiles, product portfolios, mergers and acquisitions and technology trends.
Time Frame
Base year 2025, historical data to 2022 and forecasts through 2032.
Regional Coverage
North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report provides a detailed and structured view of the drug-coated balloon market, supporting strategic planning, competitive benchmarking and product positioning.
Markets Covered and Segmentation
The report covers the Global Drug-Coated Balloon Market, segmented by indication into:
Superficial Femoral Artery Applications
This segment represents a core use case for drug-coated balloons in peripheral arterial disease treatment.
Arteriovenous Access Applications
This segment includes the use of drug-coated balloons in maintaining and restoring patency in dialysis access circuits.
Competitive Analysis
Medtronic dominated the global drug-coated balloon market in 2025, driven largely by the success of its IN.PACT Admiral drug-coated balloon. Strong clinical outcomes and multiple regulatory approvals supported its position, including expansion into arteriovenous access applications. While Medtronic remains the market leader, its share is expected to face pressure as competition increases.
Becton Dickinson was an early leader in the drug-coated balloon market with the Lutonix platform, which was the first FDA-approved device of its kind in the United States. Although the company maintained strong account presence, competition from newer devices and evolving clinical preferences is expected to reduce its relative share over time.
Boston Scientific held the third position in 2025. Its Ranger drug-coated balloon gained FDA approval for peripheral arterial disease treatment and has supported the company’s expansion in this segment. Boston Scientific’s continued investment in vascular intervention technologies positions it as a key competitor in the market.
Overall, the competitive landscape is shaped by clinical evidence, regulatory approvals and the ability to demonstrate consistent performance across different vascular indications.
Technology and Practice Trends
Advancements in coating technology are one of the most important trends in the drug-coated balloon market. Manufacturers are focusing on improving drug transfer efficiency and coating durability in order to enhance treatment outcomes.
The expansion of drug-coated balloon applications is another key trend. These devices are increasingly being used in smaller vessels, more complex lesion types and in-stent restenosis cases, broadening their clinical relevance.
Physician practice patterns are also evolving toward treatment strategies that avoid permanent implants when possible. This supports the use of drug-coated balloons as a vessel-preserving option in appropriate cases.
At the same time, ongoing evaluation of drug safety and long-term outcomes continues to shape adoption patterns. This ensures that technology development remains closely aligned with clinical evidence.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
55 pages of detailed market analysis, segmentation and forecasts.
5 charts and 23 figures illustrating market trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the strongest growth opportunities within the global drug-coated balloon market?
How are coating technologies and expanding clinical applications shaping future demand?
What impact are safety concerns and clinical evidence requirements having on adoption?
Which competitors lead the market and how are their product portfolios evolving?
How will pricing trends and reimbursement influence market expansion through 2032?
How are physicians integrating drug-coated balloons into broader treatment strategies?
The Global Drug-Coated Balloon Market Report from iData Research answers these questions with detailed segmentation, competitive analysis and forecast modeling. Use it to evaluate market opportunities, benchmark competitors and support strategic decision making in a growing vascular device category.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
By iData Research - 55 pages - 5 charts, 23 figures
Executive Summary
The global drug-coated balloon market was valued at $523 million in 2025. This market is expected to grow at a CAGR of 5% over the forecast period to reach approximately $735 million by 2032.
The full report suite on the global market for drug-coated balloons covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides detailed market valuation, unit analysis and average selling price data, along with forecasts through 2032 and historical data to 2022. The structure of this report follows the same best-practice format shown in the attached example document, ensuring consistent segmentation, competitive benchmarking and forecasting methodology .
This report provides a focused analysis of the global drug-coated balloon market, including unit sales, procedure numbers, average selling prices, market size, growth trends, market shares and forecasts. It also includes qualitative analysis of market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and competitive positioning across key players.
A key trend shaping this market is the continued refinement of coating technologies and the expansion of clinical applications. Manufacturers are improving drug delivery efficiency, coating durability and biocompatibility, which supports better clinical outcomes. At the same time, the use of drug-coated balloons is expanding beyond traditional peripheral applications into areas such as small vessels, bifurcation lesions and in-stent restenosis. These factors are supporting steady growth and reinforcing the role of drug-coated balloons as a versatile tool across multiple interventional settings.
Despite this positive outlook, the market continues to be influenced by lingering concerns around paclitaxel-based technologies. These concerns have shaped physician behavior and slowed adoption in certain regions. As a result, while the drug-coated balloon market is growing faster than many other balloon categories, its expansion remains tied to clinical confidence, continued research and the development of next-generation drug platforms.
Market Overview
The global drug-coated balloon market includes catheter-based angioplasty balloons that are coated with antiproliferative drugs designed to reduce restenosis following vessel dilation. Unlike traditional balloon angioplasty, which relies only on mechanical expansion, drug-coated balloons deliver medication directly to the vessel wall during inflation, helping prevent re-narrowing of the treated segment.
These devices are used primarily in peripheral vascular interventions, including superficial femoral artery procedures and arteriovenous access interventions. They are also gaining traction in more specialized applications, such as small vessel disease and in-stent restenosis. Their ability to treat lesions without leaving a permanent implant has made them an attractive option in cases where long-term vessel flexibility and future treatment options are important.
The drug-coated balloon market sits between standard PTA balloons and stent-based therapies. Compared with standard balloons, drug-coated balloons offer improved long-term outcomes in selected cases. Compared with stents, they provide a non-implant alternative that can reduce the risk of complications associated with permanent devices. This positioning gives them a distinct role in modern endovascular treatment strategies.
Overall, the drug-coated balloon market is characterized by steady growth, ongoing innovation and a strong link between clinical evidence and commercial performance.
Market Drivers
Drug-Coated Balloon Clinical Performance
One of the main drivers of the drug-coated balloon market is the strong clinical performance demonstrated in many studies. Clinical trials have shown that drug-coated balloons can improve long-term outcomes compared with standard balloons, particularly in reducing restenosis. This makes them an attractive option for physicians treating lesions where durability is a concern.
Because these devices do not leave a permanent implant, they also align with treatment strategies that aim to preserve vessel anatomy and maintain future treatment flexibility. This is especially important in peripheral vascular disease, where patients may require multiple interventions over time.
Increasing Adoption in Complex Lesions
The expansion of drug-coated balloon use into more complex lesion types is another key driver. These devices are being used more frequently in small vessels, bifurcation lesions and in-stent restenosis cases. As physicians gain more experience and confidence in these applications, the total addressable market continues to expand.
Below-the-knee procedures are also an important area of growth. These interventions often involve smaller vessels, where drug-coated balloons can provide an effective treatment option without the need for stent placement. As the number of these procedures increases, demand for drug-coated balloons is expected to grow alongside them.
Pricing Dynamics and Relative Value
While drug-coated balloons are more expensive than standard PTA balloons, their price point is often lower than that of stent-based therapies when considering total procedural cost. As pricing becomes more competitive and as reimbursement structures evolve, drug-coated balloons are becoming a more accessible option in many healthcare systems.
As average selling prices decline over time, adoption is expected to increase, particularly in regions where cost sensitivity has previously limited uptake. This creates a pathway for broader use and supports long-term market growth.
Expansion of Coating Technologies
Advancements in coating technology are also driving market expansion. Manufacturers are working to improve drug transfer efficiency, coating stability and overall device performance. These improvements can lead to better clinical outcomes and increased physician confidence.
In addition, research into alternative drug formulations and delivery methods may help address concerns associated with existing drug platforms. Continued innovation in this area is expected to play a key role in shaping the future of the market.
Market Limiters
Concerns Over Paclitaxel Use
One of the most significant limiters in the drug-coated balloon market is the concern over paclitaxel use. In early 2019, the market experienced a major disruption following studies that suggested a potential link between paclitaxel-coated devices and increased long-term mortality. This led to a sharp decline in physician confidence and a reduction in device usage.
Although further research has provided additional context and the market has begun to recover, the impact of these concerns is still present. Physicians remain cautious, and adoption rates have not fully returned to pre-2019 expectations. This continues to influence both unit growth and overall market value.
Dependence on Clinical Evidence
The drug-coated balloon market is highly dependent on clinical data. While strong evidence can support rapid adoption, negative or uncertain findings can have an equally strong impact in the opposite direction. This creates a level of volatility that is not present in more mature and commoditized device categories.
Manufacturers must continue to invest in clinical studies, post-market surveillance and physician education to maintain confidence and support adoption. These requirements add cost and complexity to product development and commercialization.
Slower Recovery in Certain Segments
Some segments of the drug-coated balloon market have been slower to recover following the paclitaxel-related disruption. This is particularly true in areas where alternative treatment options are readily available or where physician preference has shifted toward other technologies.
As a result, growth in these segments is expected to be gradual rather than rapid. The overall market will continue to expand, but at a pace that reflects both renewed adoption and ongoing caution.
Competitive Pressure from Alternative Therapies
Drug-coated balloons also face competition from other treatment modalities, including standard PTA balloons, stents and atherectomy devices. In some cases, physicians may choose these alternatives based on lesion characteristics, cost considerations or clinical preference.
This competitive environment means that drug-coated balloons must continue to demonstrate clear clinical value in order to maintain and grow their share within the broader peripheral vascular device market.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, competitive analysis, company profiles, product portfolios, mergers and acquisitions and technology trends.
Time Frame
Base year 2025, historical data to 2022 and forecasts through 2032.
Regional Coverage
North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report provides a detailed and structured view of the drug-coated balloon market, supporting strategic planning, competitive benchmarking and product positioning.
Markets Covered and Segmentation
The report covers the Global Drug-Coated Balloon Market, segmented by indication into:
Superficial Femoral Artery Applications
This segment represents a core use case for drug-coated balloons in peripheral arterial disease treatment.
Arteriovenous Access Applications
This segment includes the use of drug-coated balloons in maintaining and restoring patency in dialysis access circuits.
Competitive Analysis
Medtronic dominated the global drug-coated balloon market in 2025, driven largely by the success of its IN.PACT Admiral drug-coated balloon. Strong clinical outcomes and multiple regulatory approvals supported its position, including expansion into arteriovenous access applications. While Medtronic remains the market leader, its share is expected to face pressure as competition increases.
Becton Dickinson was an early leader in the drug-coated balloon market with the Lutonix platform, which was the first FDA-approved device of its kind in the United States. Although the company maintained strong account presence, competition from newer devices and evolving clinical preferences is expected to reduce its relative share over time.
Boston Scientific held the third position in 2025. Its Ranger drug-coated balloon gained FDA approval for peripheral arterial disease treatment and has supported the company’s expansion in this segment. Boston Scientific’s continued investment in vascular intervention technologies positions it as a key competitor in the market.
Overall, the competitive landscape is shaped by clinical evidence, regulatory approvals and the ability to demonstrate consistent performance across different vascular indications.
Technology and Practice Trends
Advancements in coating technology are one of the most important trends in the drug-coated balloon market. Manufacturers are focusing on improving drug transfer efficiency and coating durability in order to enhance treatment outcomes.
The expansion of drug-coated balloon applications is another key trend. These devices are increasingly being used in smaller vessels, more complex lesion types and in-stent restenosis cases, broadening their clinical relevance.
Physician practice patterns are also evolving toward treatment strategies that avoid permanent implants when possible. This supports the use of drug-coated balloons as a vessel-preserving option in appropriate cases.
At the same time, ongoing evaluation of drug safety and long-term outcomes continues to shape adoption patterns. This ensures that technology development remains closely aligned with clinical evidence.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
55 pages of detailed market analysis, segmentation and forecasts.
5 charts and 23 figures illustrating market trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the strongest growth opportunities within the global drug-coated balloon market?
How are coating technologies and expanding clinical applications shaping future demand?
What impact are safety concerns and clinical evidence requirements having on adoption?
Which competitors lead the market and how are their product portfolios evolving?
How will pricing trends and reimbursement influence market expansion through 2032?
How are physicians integrating drug-coated balloons into broader treatment strategies?
The Global Drug-Coated Balloon Market Report from iData Research answers these questions with detailed segmentation, competitive analysis and forecast modeling. Use it to evaluate market opportunities, benchmark competitors and support strategic decision making in a growing vascular device category.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Table of Contents
39 Pages
- List Of Figures
- List Of Charts
- Research Methodology
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems And Perform Secondary Research
- Step 3: Preparation For Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast And Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review And Market Release
- Step 9: Customer Feedback And Market Monitoring
- Impact Of Global Tariffs
- Drug-Coated Balloon Market
- 6.1 Executive Summary
- 6.1.1 Global Drug-Coated Balloon Market Overview
- 6.1.2 Competitive Analysis
- 6.1.3 Procedures Included
- 6.1.4 Market Included
- 6.1.5 Regions Included
- 6.2 Introduction
- 6.3 Procedure Numbers
- 6.4 Market Analysis And Forecast
- 6.5 Unit Analysis
- 6.5.1 Unit Sold By Indication
- 6.6 Drivers And Limiters
- 6.6.1 Market Drivers
- 6.6.2 Market Limiters
- 6.7 Competitive Market Share Analysis
- Abbreviations
- Chart 6-1: Drug-Coated Balloon Market, Global, 2025 & 2032
- Chart 6-2: Drug-Coated Balloon Procedures, Global, 2025
- Chart 6-3: Drug-Coated Balloon Procedures by Region, Global, 2022 – 2032
- Chart 6-4: Drug-Coated Balloon Market, Global, 2022 – 2032
- Chart 6-5: Leading Competitors, Drug-Coated Balloon Market, Global, 2025
- Figure 6-1: Drug-Coated Balloon Procedures Covered
- Figure 6-2: Drug-Coated Balloon Regions Covered, Global (1 of 2)
- Figure 6-3: Drug-Coated Balloon Regions Covered, Global (2 of 2)
- Figure 6-4: Drug-Coated Balloon Procedures by Region, Global, 2022 – 2032
- Figure 6-5: Drug-Coated Balloon Procedures by Country, North America, 2022 – 2032
- Figure 6-6: Drug-Coated Balloon Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 6-7: Drug-Coated Balloon Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 6-8: Drug-Coated Balloon Procedures by Country, Western Europe, 2022 – 2032
- Figure 6-9: Drug-Coated Balloon Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 6-10: Drug-Coated Balloon Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 6-11: Drug-Coated Balloon Procedures by Country, Middle East, 2022 – 2032
- Figure 6-12: Drug-Coated Balloon Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 6-13: Drug-Coated Balloon Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 6-14: Drug-Coated Balloon Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 6-15: Drug-Coated Balloon Procedures by Country, Africa, 2022 – 2032
- Figure 6-16: Drug-Coated Balloon Market, Global, 2022 – 2032
- Figure 6-17: Units Sold by Region, Drug-Coated Balloon Market, Global, 2022 – 2032
- Figure 6-18: Average Selling Price by Region, Drug-Coated Balloon Market, Global, 2022 – 2032 (US$)
- Figure 6-19: Market Value by Region, Drug-Coated Balloon Market, Global, 2022 – 2032 (US$M)
- Figure 6-20: Drug-Coated Balloon Unit Analysis by Indication, Global, 2022 – 2032
- Figure 6-21: Units Sold by Region, SFA Drug-Coated Balloon Market, Global, 2022 – 2032
- Figure 6-22: Units Sold by Region, AV Access Drug-Coated Balloon Market, Global, 2022 – 2032
- Figure 6-23: Leading Competitors, Drug-Coated Balloon Market, Global, 2025
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
